Nefazodone
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Nefazodone: From Antidepressant Therapy to Migraine Disorder
One-Sentence Summary
Nefazodone is pharmacologically classified as an antidepressant (5-HT2A receptor antagonist with weak serotonin/noradrenaline reuptake inhibition); no confirmed original indication text is available in the current dataset. The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 3 review-level publications currently supporting this direction — evidence is mechanistic and narrative only, not clinical-trial based.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no UK marketing authorisation or licence record on file |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L4 (mechanism/narrative review only, no RCTs) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the regulatory/DrugBank source (flagged as a High-severity data gap, DG002). Based on the repurposing rationale accompanying this prediction, Nefazodone is understood to act as a 5-HT2A receptor antagonist with weak serotonin/noradrenaline reuptake inhibition — a pharmacological profile that partially overlaps with other antidepressant classes (TCAs, SSRIs/SNRIs) already used off-label or on-label for migraine prophylaxis. This overlap provides a plausible theoretical basis for the TxGNN model’s prediction.
However, this mechanistic plausibility is undermined by two factors: first, the drug’s original indication cannot be confirmed from the available dataset, so the relationship between “original use” and “new indication” cannot be properly assessed; second, Nefazodone is not currently marketed in the UK (market status: not marketed, 0 marketing authorisations), which is consistent with the well-documented hepatotoxicity concerns that led to withdrawal of nefazodone-containing products in numerous markets. Safety concerns therefore outweigh the mechanistic rationale at this stage.
For the secondary prediction (migraine with brainstem aura), the evidence is weaker still — supported only by the TxGNN score (99.60%) with no literature or trial evidence at all. Migraine with brainstem aura is a subtype in which vasoconstrictive agents (e.g. triptans) are relatively contraindicated; if Nefazodone carries meaningful serotonergic activity, its safety profile in this specific subgroup would need particularly careful scrutiny, which cannot be performed given the current absence of evidence.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15115635 | 2004 | Review | Current Pain and Headache Reports | Reviews emerging migraine prophylaxis options; lists nefazodone alongside topiramate, levetiracetam, zonisamide, botulinum toxin and others as an emerging preventive agent |
| 15926007 | 2005 | Review | Neurological Sciences | Broad review of current and emerging migraine preventive therapies, briefly discussing nefazodone in this context |
| 15549532 | 2004 | Review | Neurological Sciences | Review of new migraine preventive drugs; notes that evidence for some agents (including nefazodone) is limited to open, uncontrolled trials rather than double-blind controlled studies |
All three sources are narrative reviews (Tier 3); none report primary controlled-trial data specific to nefazodone in migraine.
UK Market Information
No UK marketing authorisations are on file for Nefazodone. Current market status is not marketed, with 0 recorded licences. As no UK product exists, no BNF classification entry or SmPC is currently available for this substance in the UK market.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: A Blocking-severity data gap (DG001) has been identified — MHRA/regulatory warning and contraindication data for Nefazodone are not currently available in this dataset, which prevents completion of the initial safety assessment (S1 stage). Given the drug’s non-marketed status in the UK, this gap should be treated as a hard stop for any repurposing evaluation until resolved, particularly given nefazodone’s known association with hepatotoxicity signals that have affected its regulatory status in other jurisdictions.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to narrative reviews (no clinical trials, no RCTs) and a Blocking-severity safety data gap prevents even an initial safety assessment. The drug is not currently marketed in the UK, and mechanism-of-action data required to assess biological plausibility is also missing (High-severity gap).
To proceed, the following is needed:
- MHRA/SmPC warnings, contraindications, and drug interaction data (resolves DG001, Blocking)
- Confirmed mechanism of action from DrugBank or equivalent source (resolves DG002, High)
- Confirmation of the drug’s original approved indication(s), to properly assess repurposing rationale
- At minimum, prospective or retrospective clinical evidence (not review-only) specific to nefazodone in migraine before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.